Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2082) 2082
Book Review (275) 275
Publication (121) 121
Book Chapter (3) 3
Conference Proceeding (3) 3
Magazine Article (2) 2
Dissertation (1) 1
Newspaper Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (1712) 1712
humans (1193) 1193
hydrazones - therapeutic use (757) 757
animals (756) 756
pyridazines - therapeutic use (590) 590
hydrazones - pharmacology (580) 580
male (508) 508
cardiotonic agents - therapeutic use (440) 440
female (410) 410
pharmacology & pharmacy (399) 399
levosimendan (337) 337
chemistry, medicinal (309) 309
mice (299) 299
heart failure - drug therapy (298) 298
hydrazones - chemistry (297) 297
hydrazones (289) 289
analysis (247) 247
cardiac & cardiovascular systems (235) 235
biochemistry & molecular biology (226) 226
middle aged (209) 209
rats (206) 206
cancer (204) 204
pyridazines - pharmacology (204) 204
heart failure (199) 199
hydrazones - administration & dosage (188) 188
aged (182) 182
treatment outcome (182) 182
structure-activity relationship (179) 179
cell line, tumor (178) 178
derivatives (171) 171
hydrazones - chemical synthesis (165) 165
dose-response relationship, drug (154) 154
dobutamine (153) 153
apoptosis (147) 147
in-vitro (144) 144
hydrazone (140) 140
cardiotonic agents - pharmacology (138) 138
molecular structure (138) 138
pyridazines - administration & dosage (138) 138
antineoplastic agents - pharmacology (132) 132
chemistry, multidisciplinary (130) 130
pyridoxal isonicotinoyl hydrazone (125) 125
calcium sensitizer (121) 121
vasodilator agents - therapeutic use (118) 118
heart failure - physiopathology (117) 117
chemistry, organic (115) 115
abridged index medicus (112) 112
cell biology (112) 112
care and treatment (110) 110
antineoplastic agents - chemistry (108) 108
hemodynamics - drug effects (108) 108
cardiotonic agents - administration & dosage (105) 105
drugs (104) 104
oxidative stress (103) 103
time factors (102) 102
heart-failure (100) 100
research (100) 100
adult (99) 99
agents (98) 98
apoptosis - drug effects (98) 98
cytotoxicity (98) 98
cells (97) 97
design (96) 96
mortality (95) 95
health aspects (94) 94
cell survival - drug effects (92) 92
infusions, intravenous (91) 91
anesthesiology (90) 90
antineoplastic agents - therapeutic use (89) 89
efficacy (89) 89
doxorubicin (88) 88
hydrazones - adverse effects (85) 85
hydrogen-ion concentration (85) 85
ligands (85) 85
simendan (85) 85
dobutamine - therapeutic use (84) 84
cell proliferation - drug effects (83) 83
proteins (82) 82
inhibitors (81) 81
oncology (80) 80
disease models, animal (79) 79
surgery (79) 79
acute disease (78) 78
inhibition (78) 78
cell line (76) 76
drug design (75) 75
drug therapy (75) 75
neoplasms - drug therapy (75) 75
chemotherapy (74) 74
biological evaluation (73) 73
therapy (73) 73
carbonyl cyanide m-chlorophenyl hydrazone - pharmacology (72) 72
iron (72) 72
medicine & public health (72) 72
safety (72) 72
article (71) 71
cardiac patients (71) 71
critical care medicine (71) 71
antineoplastic agents - chemical synthesis (70) 70
chemistry (70) 70
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1994) 1994
German (31) 31
Spanish (23) 23
Russian (14) 14
Italian (8) 8
Chinese (5) 5
French (5) 5
Japanese (5) 5
Turkish (2) 2
Danish (1) 1
Finnish (1) 1
Hungarian (1) 1
Lithuanian (1) 1
Norwegian (1) 1
Polish (1) 1
Portuguese (1) 1
Romanian (1) 1
Serbian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Taxane-Platin-Resistant Lung Cancers Co-develop Hypersensitivity to JumonjiC Demethylase Inhibitors
by Dalvi, Maithili P and Wang, Lei and Zhong, Rui and Kollipara, Rahul K and Park, Hyunsil and Bayo, Juan and Yenerall, Paul and Zhou, Yunyun and Timmons, Brenda C and Rodriguez-Canales, Jaime and Behrens, Carmen and Mino, Barbara and Villalobos, Pamela and Parra, Edwin R and Suraokar, Milind and Pataer, Apar and Swisher, Stephen G and Kalhor, Neda and Bhanu, Natarajan V and Garcia, Benjamin A and Heymach, John V and Coombes, Kevin and Xie, Yang and Girard, Luc and Gazdar, Adi F and Kittler, Ralf and Wistuba, Ignacio I and Minna, John D and Martinez, Elisabeth D
Cell Reports, ISSN 2211-1247, 05/2017, Volume 19, Issue 8, pp. 1669 - 1684
Although non-small cell lung cancer (NSCLC) patients benefit from standard taxane-platin chemotherapy, many relapse, developing drug resistance. We established... 
lung cancer | histone methylation | taxane-platin chemotherapy | JIB-04 | GSK-J4 | KDM | histone demethylases | demethylase inhibitors | Jumonji demethylases | drug resistance | CELLS | MELANOMA | THERAPY | CHEMOTHERAPY REGIMENS | MECHANISM | GENE-EXPRESSION | LEUKEMIA | MULTIDRUG-RESISTANCE | CELL BIOLOGY | Lung Neoplasms - drug therapy | Transcription, Genetic - drug effects | Taxoids - pharmacology | Benzazepines - adverse effects | Humans | Aminopyridines - adverse effects | Lung Neoplasms - pathology | Antineoplastic Agents - therapeutic use | Gene Expression Profiling | Taxoids - therapeutic use | Hydrazones - adverse effects | Aminopyridines - therapeutic use | Carboplatin - therapeutic use | Hydrazones - therapeutic use | Jumonji Domain-Containing Histone Demethylases - antagonists & inhibitors | Bridged-Ring Compounds - pharmacology | Neoadjuvant Therapy | Antineoplastic Agents - pharmacology | Gene Expression Regulation, Neoplastic - drug effects | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Bridged-Ring Compounds - therapeutic use | Carcinoma, Non-Small-Cell Lung - genetics | Enzyme Inhibitors - pharmacology | Benzazepines - pharmacology | Pyrimidines - pharmacology | Enzyme Inhibitors - therapeutic use | Hydrazones - pharmacology | Disease-Free Survival | Drug Resistance, Neoplasm - genetics | Animals | Benzazepines - therapeutic use | Pyrimidines - therapeutic use | Aminopyridines - pharmacology | Pyrimidines - adverse effects | Cell Line, Tumor | Mice | Carcinoma, Non-Small-Cell Lung - drug therapy | Histones - metabolism | Carboplatin - pharmacology | Methylation | Jumonji Domain-Containing Histone Demethylases - metabolism | Drug Resistance, Neoplasm - drug effects | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Levosimendan vs Dobutamine for Patients With Acute Decompensated Heart Failure: The SURVIVE Randomized Trial
by Mebazaa, Alexandre and Nieminen, Markku S and Packer, Milton and Cohen-Solal, Alain and Kleber, Franz X and Pocock, Stuart J and Thakkar, Roopal and Padley, Robert J and Põder, Pentti and Kivikko, Matti and SURVIVE Investigators, for the and SURVIVE Investigators
JAMA, ISSN 0098-7484, 05/2007, Volume 297, Issue 17, pp. 1883 - 1891
CONTEXT Because acute decompensated heart failure causes substantial morbidity and mortality, there is a need for agents that at least improve hemodynamics and... 
CALCIUM SENSITIZER | CARVEDILOL | MEDICINE, GENERAL & INTERNAL | MANAGEMENT | PROTEIN | MILRINONE | EFFICACY | CARDIAC TROPONIN-C | CONTINUOUS-INFUSION | CA2+ SENSITIZER | NESIRITIDE | Acute Disease | Double-Blind Method | Humans | Middle Aged | Male | Heart Failure - blood | Heart Failure - drug therapy | Cardiotonic Agents - therapeutic use | Hydrazones - therapeutic use | Survival Analysis | Female | Aged | Infusions, Intravenous | Dobutamine - therapeutic use | Natriuretic Peptide, Brain - blood | Pyridazines - therapeutic use | Heart Failure - mortality | Heart failure | Comparative studies | Survival analysis | Peptides | Drug therapy | Mortality | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Effect of Levosimendan on the Short-Term Clinical Course of Patients With Acutely Decompensated Heart Failure
by Packer, Milton and Colucci, Wilson and Fisher, Lloyd and Massie, Barry M and Teerlink, John R and Young, James and Padley, Robert J and Thakkar, Roopal and Delgado-Herrera, Leticia and Salon, Jeffrey and Garratt, Chris and Huang, Bidan and Sarapohja, Toni and Revive Heart Failure Study Grp and REVIVE Heart Failure Study Group
JACC: Heart Failure, ISSN 2213-1779, 04/2013, Volume 1, Issue 2, pp. 103 - 111
This study evaluated the efficacy and safety of levosimendan, a positive inotropic drug with vasodilator effects, given intravenously to patients with acutely... 
trials | heart failure | inotropic agents | Heart failure | Inotropic agents | Trials | CARDIAC & CARDIOVASCULAR SYSTEMS | Cardiotonic Agents - therapeutic use | Prospective Studies | Double-Blind Method | Humans | Hydrazones - therapeutic use | Middle Aged | Female | Male | Pyridazines - therapeutic use | Heart Failure - drug therapy | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text A small molecule modulates Jumonji histone demethylase activity and selectively inhibits cancer growth
by Wang, Lei and Wang, Lei and Chang, Jianjun and Chang, Jianjun and Varghese, Diana and Varghese, Diana and Dellinger, Michael and Dellinger, Michael and Kumar, Subodh and Kumar, Subodh and Best, Anne M and Best, Anne M and Ruiz, Julio and Ruiz, Julio and Bruick, Richard and Bruick, Richard and Peña-Llopis, Samuel and Peña-Llopis, Samuel and Xu, Junjie and Xu, Junjie and Babinski, David J and Babinski, David J and Frantz, Doug E and Frantz, Doug E and Brekken, Rolf A and Brekken, Rolf A and Quinn, Amy M and Quinn, Amy M and Simeonov, Anton and Simeonov, Anton and Easmon, Johnny and Easmon, Johnny and Martinez, Elisabeth D and Martinez, Elisabeth D
Nature communications, ISSN 2041-1723, 2013, Volume 4, Issue 1, pp. 2035 - 2035
The pharmacological inhibition of general transcriptional regulators has the potential to block growth through targeting multiple tumorigenic signalling... 
TARGET | STRUCTURAL INSIGHTS | CELLS | DESIGN | JMJD2 FAMILY | MULTIDISCIPLINARY SCIENCES | GENE-EXPRESSION | PROLIFERATION | IDENTIFICATION | BINDING | REVERSAL | Small Molecule Libraries - pharmacology | Transcription, Genetic - drug effects | Humans | Isomerism | Aminopyridines - chemistry | Dose-Response Relationship, Drug | Aminopyridines - therapeutic use | Neoplasms - genetics | Hydrazones - therapeutic use | Jumonji Domain-Containing Histone Demethylases - antagonists & inhibitors | Inhibitory Concentration 50 | Antineoplastic Agents - pharmacology | Epigenesis, Genetic - drug effects | Lysine - metabolism | Cell Survival - drug effects | Enzyme Inhibitors - pharmacology | Small Molecule Libraries - therapeutic use | Antineoplastic Agents - chemistry | Enzyme Inhibitors - therapeutic use | Hydrazones - chemistry | Hydrazones - pharmacology | Neoplasms - drug therapy | Small Molecule Libraries - chemistry | Animals | Methylation - drug effects | Aminopyridines - pharmacology | Survival Analysis | Cell Line, Tumor | Cell Proliferation - drug effects | Mice | Histones - metabolism | Neoplasms - pathology | Jumonji Domain-Containing Histone Demethylases - metabolism | Drug Screening Assays, Antitumor | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Levosimendan for Hemodynamic Support after Cardiac Surgery
by Landoni, Giovanni and Lomivorotov, Vladimir V and Alvaro, Gabriele and Lobreglio, Rosetta and Pisano, Antonio and Guarracino, Fabio and Calabrò, Maria G and Grigoryev, Evgeny V and Likhvantsev, Valery V and Salgado-Filho, Marcello F and Bianchi, Alessandro and Pasyuga, Vadim V and Baiocchi, Massimo and Pappalardo, Federico and Monaco, Fabrizio and Boboshko, Vladimir A and Abubakirov, Marat N and Amantea, Bruno and Lembo, Rosalba and Brazzi, Luca and Verniero, Luigi and Bertini, Pietro and Scandroglio, Anna M and Bove, Tiziana and Belletti, Alessandro and Michienzi, Maria G and Shukevich, Dmitriy L and Zabelina, Tatiana S and Bellomo, Rinaldo and Zangrillo, Alberto and CHEETAH Study Grp and CHEETAH Study Group
The New England Journal of Medicine, ISSN 0028-4793, 05/2017, Volume 376, Issue 21, pp. 2021 - 2031
In a randomized trial, 506 patients requiring perioperative hemodynamic support after cardiac surgery were assigned to receive levosimendan or placebo in... 
MORTALITY | TRIALS | SHOCK | MEDICINE, GENERAL & INTERNAL | METAANALYSIS | MANAGEMENT | THERAPY | DECOMPENSATED HEART-FAILURE | DYSFUNCTION | OUTCOMES | SEPSIS | Humans | Middle Aged | Male | Cardiotonic Agents - therapeutic use | Cardiac Surgical Procedures | Hydrazones - adverse effects | Cardiotonic Agents - adverse effects | Hydrazones - therapeutic use | Treatment Failure | Pyridazines - administration & dosage | Female | Cardiac Output, Low - drug therapy | Postoperative Complications - drug therapy | Pyridazines - adverse effects | Pyridazines - therapeutic use | Length of Stay | Double-Blind Method | Mortality | Hydrazones - administration & dosage | Stroke Volume - drug effects | Respiration, Artificial | Perioperative Period | Cardiotonic Agents - administration & dosage | Aged | Hemodynamics - drug effects | Infusions, Intravenous | Heart | Treatment outcome | Usage | Hemodynamics | Analysis | Surgery | Heart failure | Heart surgery | Clinical trials | Drug therapy | Clinical outcomes | Pharmaceuticals | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text The effect of vasoactive drugs on mortality in patients with severe sepsis and septic shock. A network meta-analysis of randomized trials
by Belletti, Alessandro, MD and Benedetto, Umberto, MD, PhD and Biondi-Zoccai, Giuseppe, MD and Leggieri, Carlo, MD and Silvani, Paolo, MD and Angelini, Gianni D., MD and Zangrillo, Alberto, MD and Landoni, Giovanni, MD
Journal of Critical Care, ISSN 0883-9441, 2016, Volume 37, pp. 91 - 98
Abstract Purpose Inotropes and vasopressors are cornerstone of therapy in septic shock, but search for the best agent is ongoing. We aimed to determine which... 
Critical Care | Microcirculation | Sepsis | Vasopressors | Inotropes | Intensive care | Mortality | GASTRIC PERFUSION | SYSTEMATIC REVIEWS | CRITICAL ILLNESS | NOREPINEPHRINE | BLOOD-FLOW | INTENSIVE-CARE | VASOPRESSIN INFUSION | ORGAN DYSFUNCTION | GOAL-DIRECTED RESUSCITATION | MICROCIRCULATORY ALTERATIONS | CRITICAL CARE MEDICINE | Arginine Vasopressin - therapeutic use | Dopamine - therapeutic use | Vasoconstrictor Agents - therapeutic use | Norepinephrine - therapeutic use | Vasopressins - therapeutic use | Humans | Treatment Outcome | Shock, Septic - mortality | Randomized Controlled Trials as Topic | Sepsis - mortality | Cardiotonic Agents - therapeutic use | Sepsis - drug therapy | Epinephrine - therapeutic use | Hydrazones - therapeutic use | Shock, Septic - drug therapy | Network Meta-Analysis | Odds Ratio | Dobutamine - therapeutic use | Pyridazines - therapeutic use | Septic shock | Analysis | Patient outcomes | Epinephrine | Medical research | Cardiac patients | Medicine, Experimental | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Combination of drug-conjugated SWCNT nanocarriers for efficient therapy of cancer stem cells in a breast cancer animal model
by Al Faraj, Achraf and Shaik, Asma Sultana and Ratemi, Elaref and Halwani, Rabih
Journal of Controlled Release, ISSN 0168-3659, 03/2016, Volume 225, pp. 240 - 251
Targeting breast cancer and more specifically cancer stem cell (CSC) subpopulation, responsible for tumor growth, resistance and self-renewal, using... 
Salinomycin | Single walled carbon nanotubes | Breast cancer stem cells | Drug delivery system | Noninvasive imaging | Paclitaxel | DELIVERY-SYSTEMS | RESISTANCE | PHARMACOLOGY & PHARMACY | CHEMISTRY, MULTIDISCIPLINARY | CARBON NANOTUBES | CHALLENGES | Antigens, Tumor-Associated, Carbohydrate - blood | Drug Carriers - therapeutic use | Neoplastic Stem Cells - drug effects | Antibodies - chemistry | Humans | Drug Carriers - administration & dosage | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Drug Carriers - chemistry | Paclitaxel - chemistry | Pyrans - chemistry | Hydrazones - therapeutic use | Female | Paclitaxel - administration & dosage | Pyrans - therapeutic use | Antibodies - therapeutic use | Cell Survival - drug effects | Hydrazones - administration & dosage | Antineoplastic Agents - chemistry | Breast Neoplasms - drug therapy | Paclitaxel - therapeutic use | Hydrazones - chemistry | Antibodies - administration & dosage | Animals | Tumor Burden - drug effects | Breast Neoplasms - pathology | Mice, Nude | Nanotubes, Carbon - chemistry | Mucin-1 - blood | Breast Neoplasms - blood | Cell Line, Tumor | Hyaluronan Receptors - immunology | Mice, Inbred BALB C | Pyrans - administration & dosage | Drugs | Breast cancer | Transplantation | Health aspects | Stem cells | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Liver function abnormalities, clinical profile, and outcome in acute decompensated heart failure
by Nikolaou, Maria and Parissis, John and Yilmaz, M. Birhan and Seronde, Marie-France and Kivikko, Matti and Laribi, Said and Paugam-Burtz, Catherine and Cai, Danlin and Pohjanjousi, Pasi and Laterre, Pierre-François and Deye, Nicolas and Poder, Pentti and Cohen-Solal, Alain and Mebazaa, Alexandre
European Heart Journal, ISSN 0195-668X, 03/2013, Volume 34, Issue 10, pp. 742 - 749
The aim of this study was to assess the prevalence of abnormal liver function tests (LFTs) and the associated clinical profile and outcome(s) in acute... 
Heart failure | Prognosis | Inotropic agents | Liver | MORTALITY | DIAGNOSIS | CARDIAC & CARDIOVASCULAR SYSTEMS | CONGESTION | LEVOSIMENDAN | DOBUTAMINE | TRIAL | HYPOXIC HEPATITIS | CARDIORENAL SYNDROME | DYSFUNCTION | Liver Function Tests | Heart Failure - complications | Acute Disease | Prospective Studies | Cholestasis - enzymology | Cholestasis - mortality | Heart Failure - enzymology | Humans | Alkaline Phosphatase - metabolism | Male | Randomized Controlled Trials as Topic | Cardiotonic Agents - therapeutic use | Cholestasis - etiology | Hydrazones - therapeutic use | Liver Diseases - etiology | Liver Diseases - enzymology | Transaminases - metabolism | Liver Diseases - mortality | Female | Aged | Dobutamine - therapeutic use | Pyridazines - therapeutic use | Heart Failure - mortality | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Levosimendan in Patients with Left Ventricular Dysfunction Undergoing Cardiac Surgery
by Mehta, Rajendra H and Leimberger, Jeffrey D and van Diepen, Sean and Meza, James and Wang, Alice and Jankowich, Rachael and Harrison, Robert W and Hay, Douglas and Fremes, Stephen and Duncan, Andra and Soltesz, Edward G and Luber, John and Park, Soon and Argenziano, Michael and Murphy, Edward and Marcel, Randy and Kalavrouziotis, Dimitri and Nagpal, Dave and Bozinovski, John and Toller, Wolfgang and Heringlake, Matthias and Goodman, Shaun G and Levy, Jerrold H and Harrington, Robert A and Anstrom, Kevin J and Alexander, John H and LEVO-CTS Investigators
The New England Journal of Medicine, ISSN 0028-4793, 05/2017, Volume 376, Issue 21, pp. 2032 - 2042
In this trial, 882 cardiac surgical patients with left ventricular dysfunction were assigned to levosimendan or placebo. There was no between-group difference... 
MORTALITY | CALCIUM SENSITIZER | MEDICINE, GENERAL & INTERNAL | ARTERY-BYPASS SURGERY | DESIGN | RATIONALE | HEART-FAILURE | RANDOMIZED-TRIAL | CARDIOPULMONARY BYPASS | INFUSION | OUTPUT SYNDROME | Heart-Assist Devices - statistics & numerical data | Myocardial Infarction - epidemiology | Simendan | Humans | Middle Aged | Male | Cardiotonic Agents - therapeutic use | Cardiac Surgical Procedures | Hydrazones - adverse effects | Cardiotonic Agents - adverse effects | Hydrazones - therapeutic use | Treatment Failure | Female | Cardiac Output, Low - drug therapy | Postoperative Complications - drug therapy | Renal Replacement Therapy - statistics & numerical data | Pyridazines - adverse effects | Pyridazines - therapeutic use | Double-Blind Method | Mortality | Stroke Volume - drug effects | Perioperative Period | Ventricular Dysfunction, Left - drug therapy | Aged | Infusions, Intravenous | Heart failure | Heart | Treatment outcome | Usage | Analysis | Surgery | Dosage and administration | Diagnosis | Cardiovascular agents | Heart surgery | Clinical trials | Drug therapy | Clinical outcomes | Pharmaceuticals | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Identification of Hsp90 inhibitors with Anti-Plasmodium activity
by Posfai, Dora and Eubanks, Amber L and Keim, Allison I and Lu, Kuan-Yi and Wang, Grace Z and Hughes, Philip F and Kato, Nobutaka and Haystead, Timothy A and Derbyshire, Emily R
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 04/2018, Volume 62, Issue 4
Malaria remains a global health burden partly due to Plasmodium parasite resistance to first-line therapeutics. The molecular chaperone heat shock protein 90... 
Hsp90 | Plasmodium | Malaria | Host-pathogen interaction | host-pathogen interaction | HEAT-SHOCK-PROTEIN-90 | MICROBIOLOGY | FALCIPARUM GROWTH | malaria | CHAPERONE | QUANTITATIVE-ANALYSIS | DISCOVERY | LIVER-STAGE | POTENT | SHOCK-PROTEIN 90 | GELDANAMYCIN | PHARMACOLOGY & PHARMACY | C-TERMINAL DOMAIN | Humans | ortho-Aminobenzoates - therapeutic use | Antimalarials - therapeutic use | Plasmodium falciparum - drug effects | Host-Pathogen Interactions | Benzamides - therapeutic use | Sulfonamides - therapeutic use | HSP90 Heat-Shock Proteins - antagonists & inhibitors | Hydrazones - therapeutic use | HSP90 Heat-Shock Proteins - metabolism | Plasmodium falciparum - pathogenicity | Indoles - therapeutic use | Plasmodium falciparum - metabolism | Malaria - drug therapy | Malaria - metabolism | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text 1-Acylthiosemicarbazides, 1,2,4-triazole-5(4 H)-thiones, 1,3,4-thiadiazoles and hydrazones containing 5-methyl-2-benzoxazolinones: Synthesis, analgesic-anti-inflammatory and antimicrobial activities
by Salgın-Gökşen, Umut and Gökhan-Kelekçi, Nesrin and Göktaş, Özgür and Köysal, Yavuz and Kılıç, Ekrem and Işık, Şamil and Aktay, Göknur and Özalp, Meral
Bioorganic & Medicinal Chemistry, ISSN 0968-0896, 2007, Volume 15, Issue 17, pp. 5738 - 5751
A novel series of 1-acylthiosemicarbazides, 1,2,4-triazole-5-thiones, 1,3,4-thiadiazoles and hydrazones containing 5-methyl-2-benzoxazolinones was synthesized... 
Thiosemicarbazide | Triazol | Hydrazone | Analgesic-anti-inflammatory and antimicrobial activities | Thiadiazole | 2-Benzoxazolinone | CHEMISTRY, MEDICINAL | BIOCHEMISTRY & MOLECULAR BIOLOGY | CHEMISTRY, ORGANIC | hydrazone | 2-benzoxazolinone | CYCLOOXYGENASE | analgesic-anti-inflammatory and antimicrobial | ACYLARYLHYDRAZONES | triazol | ACID-DERIVATIVES | IN-VITRO | thiosemicarbazide | ANTITUBERCULOSIS ACTIVITY | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | activities | thiadiazole | NITRIC-OXIDE | 2-BENZOXAZOLINONE DERIVATIVES | AGENTS | ANTIFUNGAL | Analgesics - pharmacology | Triazoles - chemistry | Crystallography, X-Ray | Structure-Activity Relationship | Analgesics - chemical synthesis | Thiadiazoles - chemistry | Thiadiazoles - therapeutic use | Anti-Bacterial Agents - chemistry | Hydrazones - therapeutic use | Semicarbazides - pharmacology | Semicarbazides - chemistry | Anti-Inflammatory Agents - therapeutic use | Triazoles - chemical synthesis | Molecular Structure | Thiadiazoles - pharmacology | Triazoles - therapeutic use | Microbial Viability - drug effects | Anti-Inflammatory Agents - pharmacology | Models, Molecular | Edema - drug therapy | Hydrazones - chemical synthesis | Semicarbazides - therapeutic use | Hydrazones - chemistry | Hydrazones - pharmacology | Anti-Bacterial Agents - chemical synthesis | Semicarbazides - chemical synthesis | Triazoles - pharmacology | Animals | Anti-Inflammatory Agents - chemistry | Benzoxazoles - chemistry | Thiadiazoles - chemical synthesis | Analgesics - chemistry | Hindlimb - drug effects | Anti-Bacterial Agents - pharmacology | Anti-Inflammatory Agents - chemical synthesis | Mice | Methylation | Edema - pathology | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights